Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Announces Patent Protection for TAL Effector Technology

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Patent covers nucleic acids encoding Transcription Activator-Like Effector Nuclease fusion proteins (TALENS) and the formal launch of an associated sublicensing program.

The technology has broad utility in the pharmaceutical industry, synthetic biology, and plant sciences for creating genetically modified cell lines, animals and plants, and is being actively explored for potential uses in human gene therapy.

Life Technologies has exclusive rights to U.S. Patent No. 8,420,782 B2, "Modular DNA-Binding Domains and Methods of Use" issued April 16, a fundamental intellectual property for all applications of TAL effectors in fields outside commercial use in plants. Life  markets TALENS under the brand name GeneArt® Precision TAL Technology. TAL effectors bind to specific DNA sequences with higher precision than zinc finger binding proteins and can be used to deliver a variety of functional elements to activate or repress gene expression or cut and insert DNA.

"The GeneArt® Precision TAL technology is being employed in numerous commercial R&D applications, including identification of new pharmaceutical compounds, disease modeling and bioproduction technology," said Nathan Wood, general manager and vice president of synthetic biology at Life Technologies. "Their ability to bind to DNA with unprecedented precision and reliability makes TAL effectors invaluable to researchers looking to edit genomes and control gene activity."

The current patent names Jens Boch, Ulla Bonas, Thomas Lahaye and Sebastian Schornack as inventors, and is based on work conducted at Martin-Luther-Universitat Halle-Wittenberg. The Two Blades Foundation, a U.S.-based charitable organization, owns exclusive rights to commercial applications in plants and is committed to making TAL technology broadly available through licensing.

"Patent protection brings increased assurance to our industrial customers with regard to bringing new products to market," said Wood, "and for our agriculture customers, through our strong partnership with Two Blades, a path forward in commercializing their R&D efforts."

Among Life Technologies' first sublicensees of TAL technology are ToolGen, Inc., which is using the technology to generate transgenic animal models and cell lines and Cellular Dynamics International, which is applying TAL effectors to introduce or correct disease-associated mutations in induced pluripotent stem cell lines.

GeneArt® Precision TALs are supplied as Gateway® compatible entry clones encoding a DNA binding protein for a specific customer-submitted sequence fused to a range of customer selected effector domains. Custom TALs are typically delivered within two weeks after orders are placed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Atmosphere Acidity Minimised to Preindustrial Levels
Sheet ice study shows acidic pollution of the atmosphere has now almost returned to preindustrial levels.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!